The first case of COVID-19 was identified in December 2019. The disease rapidly evolved into a global pandemic and was declared a “Public Health Emergency of International Concern” by the World Health Organization (WHO) on March 11, 2020. On that same date, the first case of COVID-19 was detected in the Republic of Côte d’Ivoire. The causative agent, SARS-CoV-2, typically manifests as respiratory involvement, ranging from paucisymptomatic forms to severe pneumonia with acute respiratory distress [1]. Beyond its respiratory tropism, accumulating evidence suggests multiorgan involvement in infected patients, attributed to viral binding to angiotensin-converting enzyme 2 (ACE2) receptors expressed on various human cell types [1].

Although acute respiratory failure remains the most frequent and severe organ dysfunction, acute kidney injury (AKI) is commonly reported in patients with SARS-CoV-2 infection. AKI is a frequent complication among critically ill patients admitted to intensive care units (ICUs) for acute respiratory distress syndrome (ARDS) secondary to COVID-19. Its reported incidence in ICU settings varies from 5% to 25% across studies [2]. A study conducted in Bordeaux, France, estimated the incidence of AKI at approximately 80% among critically ill patients requiring ICU admission [3]. In a large cohort of over 1800 ICU patients with ARDS, 44.3% developed AKI, compared with 27.4% among ICU patients without ARDS [3].

The development of AKI is a negative prognostic indicator for survival in patients with COVID-19. In a study of patients aged 18 years and older hospitalized for COVID-19 across 13 hospitals in the New York metropolitan area between March 1 and April 27, 2020, and followed until hospital discharge, the incidence rates of in-hospital mortality were 10.8, 31.1, and 37.5 per 1000 patient-days among patients without AKI, those with AKI not requiring dialysis (KDIGO stages 1 - 3), and those with AKI requiring dialysis (stage 3D), respectively [4]. Using patients without AKI as the reference group, the authors observed significantly increased risks of in-hospital death for patients with AKI stages 1 - 3 (HR 5.6; 95% CI, 5.0 - 6.3) and stage 3D (HR 11.3; 95% CI, 9.6 - 13.1). Another study conducted in Ireland among ICU-admitted patients reported an incidence of dialysis-requiring AKI of 22.2%, with mortality exceeding 75% [5].

Several factors associated with mortality in the context of COVID-19 and AKI have been reported in the literature. This study aims to identify risk factors for death among patients with COVID-19 and acute kidney injury admitted to the intensive care unit of the Department of Infectious and Tropical Diseases.

This study included 289 patients with confirmed COVID-19. Among them, acute kidney injury was observed in 107 cases (37% prevalence).

The mean age of patients with AKI was 61.3 ± 13.6 years; 45.7% were aged ≥ 65 years. Male predominance was noted (male-to-female ratio: 2.68). The primary reasons for ICU admission were acute respiratory distress (ARD, 71%) and dyspnea (12.1%). Comorbidities included hypertension (67.2%), diabetes (41.1%), and obesity (14.9%). The most common clinical findings were coma (96.2%), hypoxia (SpO₂ < 92%, 77.6%), sepsis (79.4%), and oligo-anuria (62.6%). Among patients with ARDS (71%), severity was classified as severe in 50.4% and moderate in 15.8%. The qSOFA score was severe in 63.5% and critical in 25.2%.

According to KDIGO criteria, AKI was stage 3 in 52.3%, stage 2 in 16.8%, and stage 1 in 30.5%. AKI was diagnosed prior to admission in 40.1%, between 24 - 72 hours post-admission in 42.9%, and >72 hours post-admission in 16.8% (Table 1).

Table 1. General characteristics of COVID-19-positive patients with acute kidney injury (AKI).

Abbreviations: ARD = Acute Respiratory Distress; ARDS = Acute Respiratory Distress Syndrome; AKI = Acute Kidney Injury; HFNO = High-Flow Nasal Oxygen; NIV = Non-Invasive Ventilation; OTI = Orotracheal Intubation; MV = Mechanical Ventilation; OR = Odds Ratio; CI = Confidence Interval.

Anemia was observed in 62.5% of patients, with hemoglobin < 8 g/dL in 16.8%. Other laboratory abnormalities included hypoalbuminemia (66.3%) and metabolic acidosis (23.3%).

All patients received antibiotic therapy: triple therapy in 47.6% and dual therapy in 36.4%. Additional interventions included norepinephrine infusion (20.5%), oxygen therapy (78.5%), non-invasive ventilation (52.3%), orotracheal intubation (38.3%), mechanical ventilation (35.5%), and hemodialysis (36.4%) (Table 1).

Mortality occurred in 68 patients (63.5%). Survival was comparable between AKI and non-AKI patients during the first five days of ICU admission. However, from day 6 to day 30, survival was significantly better in the non-AKI group (p = 0.001) (Figure 1).

From day 1 to day 5, patients who developed AKI exhibited survival rates comparable to those without AKI, with no statistically significant difference (p = 0.073). Between day 5 and day 30, however, patients with AKI demonstrated significantly lower survival compared to those without AKI (p = 0.001).

Furthermore, survival was significantly better when AKI developed >72 hours after ICU admission (p = 0.026). Beyond day 27, survival rates converged regardless of AKI onset timing (Figure 2).

From day 1 to day 25, patients who developed AKI prior to admission and those who developed AKI within 24 - 72 hours after admission had lower survival compared to patients who developed AKI ≥ 72 hours after admission, with a statistically significant difference (p = 0.026). From day 27 onward, survival was

Figure 1. Survival curves of patients with and without acute kidney injury (AKI).

Figure 2. Survival curve according to the time of AKI onset.

similar regardless of the timing of kidney injury onset.

In univariate analysis, deceased patients were significantly more likely to have experienced ARD (p = 0.001), severe ARDS (p = 0.007), KDIGO stage 3 AKI (p = 0.01), blood urea > 2 g/L (p = 0.02), triple antibiotic therapy (p = 0.008), norepinephrine use (p = 0.001), neurosedation (p < 0.001), neuromuscular blockade (p = 0.002), orotracheal intubation (p < 0.001), mechanical ventilation (p < 0.001), and hemodialysis (p = 0.009) (Table 1).

Hemodialysis was indicated in cases of anuria lasting more than 24 hours, severe uremia exceeding 2 g/L, severe metabolic acidosis, and acute pulmonary edema refractory to diuretics. This was intermittent hemodialysis, not continuous hemodialysis.

In multivariate analysis, the following factors were independently associated with increased risk of death: acute respiratory distress (OR = 5.06; p = 0.006), KDIGO stage 3 AKI (OR = 5.15; p = 0.003), orotracheal intubation (OR = 4.37; p < 0.001), and mechanical ventilation (OR = 4.01; p < 0.001) (Table 2).

Table 2. Factors associated with risk of death — multivariate logistic regression analysis.

Although COVID-19 primarily manifests with respiratory symptoms, systemic complications involving the coagulation system, gastrointestinal tract, heart, and kidneys have been widely reported. Renal manifestations most commonly present as acute kidney injury (AKI), which is recognized as an independent predictor of poor prognosis in patients with SARS-CoV-2 infection.

Our study demonstrated that, starting from the sixth day of hospitalization, the presence of AKI significantly and negatively impacts patient prognosis. A retrospective study conducted between April 2020 and October 2021 in a private hospital in Kenya, involving 1366 hospitalized COVID-19 patients, similarly found that AKI was associated with a higher risk of mortality, with risk increasing proportionally with AKI stage [15].

In our cohort, more than six out of ten patients with COVID-19 and AKI died. Alfano et al. reported a mortality rate of 56.5% in a study conducted in Italy [16]. Another study from Pakistan documented a mortality rate of 62.1% among COVID-19 patients with AKI, compared to 31.4% in those without AKI [17]. Furthermore, a systematic review encompassing 142 studies and 49,048 COVID-19 patients—including 5152 cases of AKI—confirmed that AKI is independently associated with increased mortality risk [18]. Identifying risk factors for death may facilitate the development of targeted strategies to prevent renal injury, as AKI has been shown to increase in-hospital mortality risk by approximately five-fold [19]. Early identification of high-risk patients, implementation of preventive measures, and timely supportive interventions in predisposed individuals could improve outcomes and mitigate long-term sequelae.

In our study, seven out of ten patients were admitted due to acute respiratory distress (ARD), and multivariate analysis confirmed ARD as an independent predictor of mortality. A multicenter study in Saudi Arabia involving 340 ICU-admitted patients reported an ARD incidence of 81.2% [20]. Similarly, Alfano et al. identified ARD as the leading cause of death among COVID-19 patients with AKI [16].

More than half of our patients presented with KDIGO stage 3 AKI, and this advanced stage was independently associated with increased mortality (Table 1 and Table 2). Ng et al. reported similarly elevated mortality rates in patients with AKI, whether requiring dialysis (adjusted HR 6.4; 95% CI, 5.5 - 7.6) or not (adjusted HR 3.4; 95% CI, 3.0 - 3.9), compared to those without AKI [4].

Interestingly, our data showed improved survival when AKI was diagnosed more than 72 hours after ICU admission (Figure 2). This may reflect more timely and aggressive clinical interventions initiated once AKI is recognized, potentially mitigating further organ damage.

In our cohort, 36.4% of patients received hemodialysis. Cheruiyot et al. reported a lower rate of 15.6% (10 out of 64 patients) [15]. Access to renal replacement therapy in this context is heavily influenced by local resource availability and clinical decision-making. In our setting, two dialysis machines were available in the dedicated COVID-19 ICU, and nephrologists often adopted a “watchful waiting” approach before initiating dialysis. However, given the profound impact of factors such as baseline estimated glomerular filtration rate (eGFR) reduction and oliguria, it is clinically reasonable to assess individual probabilities of renal recovery and overall survival when discussing goals of care. The Renal Physicians Association recommends shared decision-making to evaluate whether to initiate dialysis, conduct a time-limited trial of dialysis, or transition to palliative or end-of-life care [21].

Critically ill COVID-19 patients receiving hemodialysis frequently develop hypoxemia, respiratory failure, and other extrapulmonary complications—including increased risks of shock, worsening AKI, and thromboembolic events. As the disease progresses, these patients often require mechanical ventilation and intensive monitoring in the ICU [22]. Contrary to our findings, some authors have suggested that ICU admission and respiratory support are not independent predictors of mortality or poor outcomes [22]. However, in our cohort, orotracheal intubation and mechanical ventilation were strongly associated with mortality (Table 2). This discrepancy may be explained by the fact that most critically ill dialysis-dependent patients also require intubation and mechanical ventilation. Intubation itself has been associated with increased risks of nosocomial infection and mortality [22]. Therefore, a critical question remains: Is mortality driven by the act of intubation itself—or by the underlying severity of illness that necessitates such invasive respiratory support?

Acute kidney injury (AKI) is a significant negative prognostic factor in patients with COVID-19. Mortality appears to be primarily associated with the severity of SARS-CoV-2 infection itself, rather than with the use of respiratory support interventions.

We would like to thank Prof. Serge Paul Eholié and the Infectious and Tropical Diseases Department for allowing us to conduct this study.

KONAN SERGE DIDIER wrote this article, conducted the study and entered the data. He carried out the statistical analysis of the data. OUATTARA KOLO CLAUDE directed this work from the protocol to the final draft. YAO Hubert coordinated the study and publication of this article.

OUATTARA KOLO CLAUDE submitted the article online and adapted it to the journal’s recommendations.

All recorded data will remain strictly confidential and can only be consulted by the medical team in charge of the research. These data will be subject to computer processing. They can be consulted on request addressed to YAO KOUAME HUBERT.

Participation in the study was not subject to financial compensation for the participants.

This study was funded by the authors with their own funds.

The participants were submitted to a confidential questionnaire, and in order to preserve their anonymity a unique number was assigned to them.

Participation in this study was entirely free and voluntary. Participants were free to accept or refuse to participate in our study. Those who accepted were also free, at any time, to end their participation, and, on simple verbal notice without giving an explanation

The results of this study had been submitted only to BMC journal. The manuscript is not under consideration by another journal and has not been previously published.

Not applicable.

The study was conducted in accordance with good clinical practice and national research guidelines. The full study protocol was approved by the Ethics and Scientific Committee of the Treichville University Hospital, in accordance with the Declaration of Helsinki. Informed consent from patients was obtained for their inclusion in the study. To respect the confidentiality of patient records, names were not mentioned, and data collection was carried out during our daily practice.

Consent to Publish declarations: not applicable.